65 completed, 17 recruiting, 16 terminated, 14 unknown. 132 Phase 2, 18 Phase 1, 3 Phase 3.
Follow Axitinib: new trials by email Literature Review of Axitinib trials Research Report on Axitinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MANTIS-RCC: Toripalimab-Axitinib Induction in TLS-Positive Advanced Non-Clear Cell and Renal Medullary Carcinomas Toripalimab, Axitinib, Deferred Cytoreductive Nephrectomy - Metastatic Non-Clear Cell Renal Cell Carcinoma, Metastatic Renal Medullary Carcinomas | Phase 2 | Not yet recruiting | Fudan University | 30 | 2026-09-20 | 2026-09-14 |
| TACTIC-RCC: Toripalimab Plus Axitinib Induction With Selective Deferred Cytoreductive Nephrectomy in TLS-Positive Advanced Clear Cell Renal Cell Carcinoma Toripalimab, Axitinib, Deferred Cytoreductive Nephrectomy - Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma | Phase 2 | Not yet recruiting | Fudan University | 30 | 2026-08-20 | 2026-08-20 |
| SABR Combined With Axitinib and Toripalimab for Oligometastatic Renal Cell Carcinoma axitinib plus toripalimab, SABR - Oligometastatic Clear Cell Renal Cell Carcinoma | Phase 2 | Recruiting | Hebei Medical University Fourth Hospital | 48 | 2026-08-15 | 2026-08-04 |
| PTC-Guided Atorvastatin Plus Axitinib and Toripalimab in Advanced RCC Axitinib, Toripalimab, Atorvastatin - Advanced Renal Cell Carcinoma (RCC), PTC | Phase 1 / Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 40 | 2026-05-14 | 2026-06-05 |
| An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma SLC-3010 + Axitinib, Axitinib - Clear Cell Renal Cell Carcinoma, Neoplasms | Phase 2 | Recruiting | Yonsei University | 78 | 2026-03-01 | 2026-03-13 |
| Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy Iparomlimab and Tuvonralimab Injection in combination with Lenvatinib or Axitinib - RCC, Renal Cell Cancer | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 36 | 2026-02-15 | 2025-12-11 |
| Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer PF-08634404, Ipilimumab, Axitinib - Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | Pfizer | 224 | 2026-02-10 | 2026-10-08 |
| A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma Sasanlimab, Palbociclib, Axitinib - Metastatic Renal Cell Carcinoma, Metastatic Renal Cancer | Phase 2 | Recruiting | Stephanie Berg | 25 | 2025-11-24 | 2026-08-20 |
| Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma Envafolimab Injection, Axitinib Tablets - Advanced Renal Cell Carcinoma (aRCC) | Phase 2 | Not yet recruiting | Peking Union Medical College Hospital | 30 | 2025-09-01 | 2025-09-08 |
| Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC Toripalimab and axitinib - Renal Cell Carcinoma (RCC) | Phase 2 | Recruiting | Tianjin Medical University Second Hospital | 40 | 2025-07-31 | 2025-09-16 |
| A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer BL-B01D1, Axitinib, Lenvatinib - Renal Cancer | Phase 2 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 260 | 2025-07-28 | 2025-11-17 |
| Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC Pembrolizumab, Axitinib - Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma | Phase 2 | Suspended | H. Lee Moffitt Cancer Center and Research Institute | 75 | 2025-02-25 | 2026-03-06 |
| Combination of Toripalimab and JS004 Therapy for ccRCC JS004, Toripalimab, Axitinib - Clear Cell Renal Cell Carcinoma | Phase 2 | Recruiting | Fudan University | 80 | 2024-06-01 | 2024-11-15 |
| Avelumab, Palbociclib and Axitinib in Advanced RCC Axitinib, Palbociclib, Avelumab - Advanced Clear Cell Renal Cell Carcinoma | Phase 2 | Withdrawn | Bradley A. McGregor, MD | 2024-05-31 | 2023-09-07 | |
| A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors INCB099280, axitinib - Advanced Solid Tumors | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 5 | 2024-04-16 | 2026-06-04 |
| Upfront Immune Checkpoint Inhibitors With Deferred Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Toripalimab, Cytoreductive Nephrectomy, Axitinib - Immune Checkpoint Inhibitors, Cytoreductive Nephrectomy | Phase 2 | Active not recruiting | RenJi Hospital | 21 | 2024-03-01 | 2026-10-27 |
| Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma PD-(L)1 inhibitor, Axitinib - Collecting Duct Carcinoma | Phase 2 | Recruiting | Peking University Cancer Hospital & Institute | 30 | 2024-02-09 | 2024-11-26 |
| Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus Axitinib, Pembrolizumab - Renal Cancer, Kidney Cancer | Phase 2 | Recruiting | University of Colorado, Denver | 17 | 2023-12-04 | 2026-04-13 |
| A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma AK104, Axitinib - Renal Cell Carcinoma, First-line Treatment | Phase 1 / Phase 2 | Active not recruiting | Hao Zeng | 37 | 2023-11-17 | 2026-04-07 |
| The Efficacy and Safety of KN046 Combined With Axitinib KN046 plus Axitinib - NSCLC | Phase 2 / Phase 3 | Unknown | Shanghai Pulmonary Hospital, Shanghai, China | 20 | 2023-08-25 | 2023-08-31 |
Showing 20 of 132. Sign in to see all of them.
Carcinoma, Renal Cell (45) · Kidney Neoplasms (11) · Carcinoma, Non-Small-Cell Lung (9) · Neoplasm Metastasis (8) · Neoplasms (6) · Carcinoma, Hepatocellular (5) · Clear-cell metastatic renal cell carcinoma (5) · Colorectal Neoplasms (5) · Melanoma (5) · Carcinoma (4) · Lung Neoplasms (4) · Recurrence (4) · Glioblastoma (3) · Carcinoma, Adenoid Cystic (2) · Endometrial Neoplasms (2)
Pfizer (20) · Chinese University of Hong Kong (3) · Fudan University (3) · H. Lee Moffitt Cancer Center and Research Institute (3) · M.D. Anderson Cancer Center (3) · Memorial Sloan Kettering Cancer Center (3) · National Cancer Institute (NCI) (3) · Peking University Cancer Hospital & Institute (3) · The Netherlands Cancer Institute (3) · Tianjin Medical University Second Hospital (3) · Case Comprehensive Cancer Center (2) · Centre Leon Berard (2) · Consorzio Oncotech (2) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (2) · Peking Union Medical College Hospital (2)
United States (65) · China (26) · United Kingdom (14) · Spain (13) · Italy (12) · South Korea (10) · France (9) · Canada (8) · Germany (8) · Poland (8) · Czechia (6) · Japan (6) · Belgium (5) · Taiwan (5) · Australia (4)
Roberto Iacovelli (2) · Abhishek Tripathi, MD (1) · Adil Daud, MD (1) · Alan L. Ho, MD, PhD (1) · Alexander Shoushtari, MD (1) · Alfredo Carrato, MD, PhD (1) · Amado J Zurita Saavedra (1) · Andrea B Apolo, M.D. (1) · Ann-Lii Cheng, MD, PhD (1) · Anthony Chan, MD (1) · Anthony TC Chan, MD, FRCP (1) · Antonio Fojo, MD (1) · Antonio T Fojo, M.D. (1)
PMID 11251976, PMID 11574279, PMID 14525967, PMID 16682732, PMID 18514303, PMID 19188168, PMID 19269895, PMID 21889330, PMID 23605883, PMID 23749461, PMID 23981851, PMID 24140184, PMID 24356624, PMID 24423921, PMID 24560330, PMID 24766732, PMID 24844950, PMID 25197551, PMID 25283266, PMID 25315258, PMID 25409260, PMID 25689070, PMID 25858804, PMID 25929582, PMID 26040622, PMID 26095784, PMID 26386123, PMID 26450920, PMID 26959385, PMID 27238653, PMID 27645897, PMID 28011330, PMID 28378918, PMID 28410911, PMID 28434648, PMID 28640364, PMID 28950297, PMID 29069302, PMID 29439857, PMID 29860482, PMID 30082870, PMID 30190302, PMID 30470260, PMID 30616534, PMID 30642373, PMID 30779531, PMID 30951193, PMID 31023100, PMID 31078463, PMID 31427205
2017 (3), 2008 (2), 2005 (1), 2023 (1), 2025 (1), P30CA014089 (1), P30CA016056 (1), U10CA180868 (1), U10CA180886 (1)